Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
$2.39M
Mr. Gerald T. Proehl
8.00
San Diego, CA
Jul 31, 2015
-0.08
$-18.73
2.58
2.73
0.00%
-0.09
0.00
0.27
0.00
2.73
-187.46%
-197.44%
Similar stocks (13)
Immix Biopharma, Inc.
IMMX
Cardio Diagnostics Holdings, Inc.
CDIO
180 Life Sciences Corp.
ATNF
Hepion Pharmaceuticals, Inc.
HEPA
Sonnet BioTherapeutics Holdings, Inc.
SONN
Windtree Therapeutics, Inc.
WINT
Revelation Biosciences, Inc.
REVB
Ensysce Biosciences, Inc.
ENSC
ZyVersa Therapeutics, Inc.
ZVSA
Phio Pharmaceuticals Corp.
PHIO
Panbela Therapeutics, Inc.
PBLA
Navidea Biopharmaceuticals, Inc.
NAVB
eFFECTOR Therapeutics, Inc.
EFTR
Similar stocks (13)
Immix Biopharma, Inc.
IMMX
Cardio Diagnostics Holdings, Inc.
CDIO
180 Life Sciences Corp.
ATNF
Hepion Pharmaceuticals, Inc.
HEPA
Sonnet BioTherapeutics Holdings, Inc.
SONN
Windtree Therapeutics, Inc.
WINT
Revelation Biosciences, Inc.
REVB
Ensysce Biosciences, Inc.
ENSC
ZyVersa Therapeutics, Inc.
ZVSA
Phio Pharmaceuticals Corp.
PHIO
Panbela Therapeutics, Inc.
PBLA
Navidea Biopharmaceuticals, Inc.
NAVB
eFFECTOR Therapeutics, Inc.
EFTR